HLA-A2.1/B2M

Nomenclature

C57BL/6JSmo-B2mtm1(hB2M-linker-HLA-A*0201/H2-D1)Smoc

Cat. NO.

NM-HU-241353

Strain State

Repository Live

Export PDF

Gene Summary

Gene Symbol
B2M

Model Description

The endogenous mouse B2m gene was replaced by hB2M-linker-HLA-A*0201/H2-D1 gene.

Validation Data

image.png

Fig.1 Detection of hB2M expression in Blood in WT C57BL 6 and HO HLA-A2.1/B2M mice.

image.png

Fig.2 Detection of HLA-ABC expression in Blood in WT C57BL/6 and HO HLA-A2.1/B2M mice.

image.png

Fig.3 Detection of vaccine-induced immune responses in HLA-A2.1/B2M mice by ELISpot assay.

Under peptide pool stimulation, both WT mice and HLA-A2.1/B2M mice mounted cellular immune responses, with the latter exhibiting stronger responses. Upon stimulation with NY-ESO-1157-165, WT mice showed no response, whereas HLA-A2.1/B2M mice generated a robust cellular immune response, demonstrating that this mouse model can effectively present the hHLA-A2.1-restricted dominant epitope NY-ESO-1157-165.

image.png

Fig.4 T-cell intracellular cytokine staining (ICS) assays.

Upon stimulation with the hHLA-A2.1-restricted dominant epitope NY-ESO-1157-165, only HLA-A2.1/B2M mice generated a large number of IFN-γ-positive CD8 T cells.


You may also like

Workshop:Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more

Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!

At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.

Learn more